Here’s an interesting take on an innovative approach to treating hair loss:
-
Minoxidil, found in well-known products like Rogaine, is often used for hair loss treatment but struggles with water solubility and skin absorption.
-
A recent study combines minoxidil with a microneedling technique and incorporates stevioside, a natural sweetener derived from the Stevia plant.
-
When tested on mice, researchers observed that the inclusion of steviosides enhanced the absorption of minoxidil, leading to improved results.
Most people aren’t really thrilled about going bald. It’s quite the industry, really—a multi-billion dollar one at that. Androgenetic alopecia, more commonly known as pattern hair loss, affects around 50% of both men and women. Minoxidil, originally developed for high blood pressure, has become a go-to solution for many dealing with baldness.
However, while it’s beneficial for some, there are some drawbacks. Traditional treatments often have poor solubility and absorption, prompting some experts to use microneedling—where tiny holes are made in the skin—to help medication penetrate more effectively.
A study from 2025 unveiled by scientists from China and Australia introduced a dissolving patch that uses microneedling and delivers minoxidil directly to the scalp, featuring a rather unexpected ingredient: stevioside. The study findings were shared in the journal Advanced Healthcare Materials.
The authors explained that by using stevioside as a solubilizing agent, they were able to incorporate minoxidil into a dissolving microneedle patch, which could enhance its effectiveness. This method addresses some downsides of conventional topical treatments, like slow onset and dosing inaccuracies.
Interestingly, while testosterone isn’t the direct cause of hair loss, an enzyme converts it into dihydrotestosterone, which can lead to the death of hair-producing cells. Minoxidil, on the other hand, works by suppressing certain enzymes and inhibiting androgen receptors, which ultimately helps reduce the effects of dihydrotestosterone. It even boosts the conversion of testosterone into estradiol, a type of estrogen that supports hair growth.
In their tests, researchers used mouse models with androgenetic alopecia to evaluate their new patch against standard therapies. Remarkably, they found hair regrowth in 67% of the treated area in just 35 days, which is promising compared to only 25% in the control group. It’s a great start, although one has to wonder how this translates to humans.
“While results in mice are encouraging, human hair growth cycles can differ, and many factors influence androgenetic alopecia,” said Lifeng Kang, a study co-author from the University of Sydney. “Therefore, clinical trials are crucial to establish safety and efficacy in humans.”
So, while the struggle with hair loss persists, it seems science is making strides—a bit of hope for those affected.
